ClinicalTrials.gg
RecruitingNCT06523504atropineUpdated Sep 8, 2025

Atropine (0.02%, 0.04%) Combined With Defocus DIMS for Moderate and High Myopia Control

A Phase 1/2 interventional study of DIMS and The 0.02% ATP Group in Myopia, sponsored by Ruihua Wei. Recruiting at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Ruihua Wei · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Feb 2024, registered Jul 2024).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
410
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 220 studies in Myopia with a site in China — 81 open to participants now, 101 under way, 4 of them phase 3. Myopia · China.

Planned enrollment
29th of 154
410 · median 149
Started
2024
with 22 others
Phase 1/2
2 of 220
1 open now
Primary completion
2026-03
later than 34 of 100 live
Registered
138th of 220
by date
Lead sponsor
5 of 220
Ruihua Wei

Among the 220 studies in Myopia with a site in China, this one is the 29th largest by planned enrollment of the 154 interventional ones that give a count, is one of 23 that started in 2024, is one of 2 in phase 1/2, reaches primary completion later than 34 of the 100 other live ones, and was the 138th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

81 of the 220 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

76 more — sign in →

All 81 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 6 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

To evaluate the effectiveness and safety of DIMS, low concentration atropine eye drops,and atropine combined with DIMS in controlling axial length and refraction in children with moderate to high myopia.

Read the detailed description

In this study, stratified block randomization was employed for random grouping, and the total sample size required as calculated was 410 individuals. Firstly, 410 subjects were assigned ID numbers ranging from 1 to 410. SPSS.26 statistical software was utilized to apply the "random number generator" by setting the "fixed seed number" to "20231121", and subsequently generate random numbers. Once the random numbers were obtained, random sampling and grouping were conducted. This study was a multicenter trial, with block randomization stratified by center. The total sample size of 410 was distributed across 4 cities, and the samples collected in each city were randomly allocated into 5 treatment groups (groups A, B, C, D, and E), with approximately 20 individuals in each group.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • School-age children aged 6 to 12 years (including boundary value)
  • Children with moderate or high myopia (subjective refraction after cycloplegia: -9.00D≤spherical equivalent (SE)≤-3.00D, with-rule astigmatism (C)≤2.00D, against-rule astigmatism (C)≤1.00D, anisometropia of both eyes≤2.50D)
  • Binocular best corrected visual acuity (BCVA)≥0.8 (five-point visual acuity 4.9)
  • Agree with the study scheme and sign the
  • Note: if both eyes meet the inclusion criteria, the eye with higher spherical equivalent is the study eye; if one eye meets the inclusion criteria, the eye is the study eye.

Exclusion criteria

Exclusion Criteria:

  • Used or currently using orthokeratology, multifocal contact lenses, defocusing framework lenses, atropine eye drops and other myopia control means in the past month; used red light treatment in the past
  • Children with obvious strabismus and amblyopia
  • With congenital eye disease, such as congenital cataract, congenital retinal disease
  • Secondary myopia (such as premature retinopathy or other eye diseases in infants and children caused secondary myopia), or myopia combined with systemic syndrome (such as Marfan syndrome)
  • Had internal eye surgery (such as cataract extraction, intraocular lens implantation, anti-glaucoma surgery, etc.)
  • Refractive medium opacity (such as corneal disease, crystal opacity, etc.)
  • Bnormal intraocular pressure and clinical significance (IOP \<10 mmHg or IOP >21mmHg or binocular IOP difference ≥5mmHg)
  • Fundus chorioretinopathy (except for high myopia fundus degenerative changes) or other intraocular diseases
  • Optic nerve damage or congenital optic nerve dysfunction
  • Can not be regularly checked
  • The adjustment range is less than 8D or obvious near difficulties
  • Other reasons researchers think it is not suitable for inclusion in researchers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
410 participants (estimated)

Study arms

  • Experimental
    The DIMS Group

    wear DIMS ,and use placebo,once nightly, both eye

    Device: DIMS

  • Experimental
    0.02% ATP

    wear SP, and use 0.02%ATP eye drops, once nightly, both eye

    Drug: The 0.02% ATP Group

  • Experimental
    0.04%ATP

    wear SP, and use 0.04%ATP eye drops, once nightly, both eye

    Drug: The 0.04% ATP Group

  • Experimental
    0.02%ATP+DIMS

    wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye

    Combination Product: 0.02%ATP+DIMS

  • Experimental
    0.04%ATP+DIMS

    wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye

    Combination Product: 0.04%ATP+DIMS

Interventions

  • DeviceDIMS

    wear DIMS ,and use placebo,once nightly, both eye

  • DrugThe 0.02% ATP Group

    wear SP, and use 0.02%ATP eye drops, once nightly, both eye

  • DrugThe 0.04% ATP Group

    wear SP, and use 0.04%ATP eye drops, once nightly, both eye

  • Combination product0.02%ATP+DIMS

    wear DIMS, and use 0.02%ATP eye drops, once nightly, both eye

  • Combination product0.04%ATP+DIMS

    wear DIMS, and use 0.04%ATP eye drops, once nightly, both eye

06

What researchers measure

Primary outcomes

  1. Best Corrected Visual Acuity

    Best Corrected Visual Acuity

    Time frame: up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2024
First posted
Jul 26, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Mar 31, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06523504
Lead sponsor
Ruihua Wei
Responsible party
Ruihua Wei (Professor, Tianjin Medical University Eye Hospital) — Sponsor-investigator
First posted
Jul 26, 2024
Start date
Feb 1, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Mar 31, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Meinan He
Contact
hmn509@tmu.edu.cn
+8613672135765

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion